1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Future Estimates
3.2.2. Currency Coverage and Foreign Exchange Rate
3.2.2.1. Major Currencies Affecting the Market
3.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rate
3.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market
3.2.2.4. Strategies for Mitigating Foreign Exchange Risk
3.2.3. Trade Policies
3.2.3.1. Impact of Trade Barriers on the Market
3.2.3.2. Strategies for Mitigating the Risk Associated with Trade Barriers
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY5. INTRODUCTION
5.1. Chapter Overview
5.2. Neurovascular Disorders
5.3. Historical Milestones in the Neurovascular Disorders Treatment
5.4. Treatment of Neurovascular Disorders
5.5. Types of Neurovascular Devices
5.6. Recent Advancements in Neurovascular Devices
5.7. Challenges Associated with Neurovascular Devices
5.8. Future Perspectives
6. MARKET LANDSCAPE
6.1. Chapter Overview
6.2. Neurovascular Devices Market: Overall Market Landscape
6.2.1. Analysis by Status of Development
6.2.2. Analysis by Type of Device
6.2.3. Analysis by Therapeutic Application
6.2.4. Analysis by Type of Device and Therapeutic Application
6.2.5. Analysis by Material of Fabrication
6.2.6. Analysis by Coating Material of Device
6.3. Neurovascular Devices Market: Developer Landscape
6.3.1. Analysis by Year of Establishment
6.3.2. Analysis by Company Size
6.3.3. Analysis by Location of Headquarters (Region)
6.3.4. Analysis by Location of Headquarters (Country)
6.3.5. Analysis by Company Size and Location of Headquarters (Region)
6.3.6. Most Active Developers: Analysis by Number of Neurovascular Devices Developed
7. COMPANY PROFILES
7.1. Chapter Overview
7.2. Johnson & Johnson
7.2.1. Company Overview
7.2.2. Financial Information
7.2.3. Neurovascular Device Portfolio
7.2.4. Recent Developments and Future Outlook
7.3. Medtronic
7.3.1. Company Overview
7.3.2. Financial Information
7.3.3. Neurovascular Device Portfolio
7.3.4. Recent Developments and Future Outlook
7.4. MicroVention
7.4.1. Company Overview
7.4.2. Financial Information
7.4.3. Neurovascular Device Portfolio
7.4.4. Recent Developments and Future Outlook
7.5. Penumbra
7.5.1. Company Overview
7.5.2. Financial Information
7.5.3. Neurovascular Device Portfolio
7.5.4. Recent Developments and Future Outlook
7.6. Stryker
7.6.1. Company Overview
7.6.2. Financial Information
7.6.3. Neurovascular Device Portfolio
7.6.4. Recent Developments and Future Outlook
7.7. Other Leading Players
7.7.1. Acandis
7.7.1.1. Company Overview
7.7.1.2. Neurovascular Device Portfolio
7.7.2. Achieva Medical
7.7.2.1. Company Overview
7.7.2.2. Neurovascular Device Portfolio
7.7.3. Balt
7.7.3.1. Company Overview
7.7.3.2. Neurovascular Device Portfolio
7.7.4. HeMo Bioengineering
7.7.4.1. Company Overview
7.7.4.2. Neurovascular Device Portfolio
7.7.5. Phenox
7.7.5.1. Company Overview
7.7.5.2. Neurovascular Device Portfolio
7.7.6. Shanghai HeartCare Medical Technology
7.7.6.1. Company Overview
7.7.6.2. Neurovascular Device Portfolio
7.7.7. Zylox-Tonbridge
7.7.7.1. Company Overview
7.7.7.2. Neurovascular Device Portfolio
8. PRODUCT COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodology
8.4. Product Competitiveness Analysis: Analysis by Location of Headquarters of Neurovascular Device Developers
8.4.1. Product Competitiveness Analysis: Neurovascular Devices Developed by Players based in North America
8.4.2. Product Competitiveness Analysis: Neurovascular Devices Developed by Players based in Europe
8.4.3. Product Competitiveness Analysis: Neurovascular Devices Developed by Players based in Asia-Pacific and Rest of the World
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Neurovascular Devices Market: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Type of Partner
9.3.5. Analysis by Year of Partnership and Type of Partner
9.3.6. Analysis by Type of Partnership and Type of Partner
9.3.7. Analysis by Type of Device
9.3.8. Analysis by Therapeutic Application
9.3.9. Most Active Players: Analysis by Number of Partnerships
9.3.10. Analysis by Geography
9.3.10.1. Local and International Agreements
9.3.10.2. Intracontinental and Intercontinental Agreements
10. FUNDING AND INVESTMENTS
10.1. Chapter Overview
10.2. Funding Models
10.3. Neurovascular Devices Market: Funding and Investments
10.3.1. Analysis by Year of Funding
10.3.2. Analysis by Type of Funding
10.3.3. Analysis by Year and Type of Funding
10.3.4. Analysis by Amount Invested
10.3.5. Analysis of Amount Invested by Type of Funding
10.3.6. Analysis by Geography
10.3.7. Most Active Players: Analysis by Number of Funding Instances
10.3.8. Most Active Players: Analysis by Amount Raised
10.3.9. Leading Investors: Analysis by Number of Funding Instances
10.4. Concluding Remarks
11. DEMAND ANALYSIS
11.1. Chapter Overview
11.2. Assumptions and Methodology
11.3. Neurovascular Devices: Global Annual Demand
11.3.1. Analysis by Type of Device
11.3.2. Analysis by Therapeutic Application
11.3.3. Analysis by Key Geographical Regions
12. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
12.1. Chapter Overview
12.2. Market Drivers
12.3. Market Restraints
12.4. Market Opportunities
12.5. Market Challenges
12.6. Conclusion
13. GLOBAL NEUROVASCULAR DEVICES MARKET
13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. Global Neurovascular Devices Market, till 2035
13.3.1. Scenario Analysis
13.3.1.1. Conservative Scenario
13.3.1.2. Optimistic Scenario
13.4. Key Market Segmentations
14. NEUROVASCULAR DEVICES MARKET, BY TYPE OF DEVICE
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. Neurovascular Devices Market: Distribution by Type of Device, 2019, current year and 2035
14.4. Neurovascular Devices Market for Neurothrombectomy Devices, till 2035
14.5. Neurovascular Devices Market for Embolization Devices, till 2035
14.6. Neurovascular Devices Market for Angioplasty Devices, till 2035
14.7. Data Triangulation and Validation
15. NEUROVASCULAR DEVICES MARKET, BY THERAPEUTIC APPLICATION
15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Neurovascular Devices Market: Distribution by Therapeutic Application, 2019, current year and 2035
15.4. Neurovascular Devices Market for Ischemic Stroke, till 2035
15.5. Neurovascular Devices Market for Aneurysm, till 2035
15.6. Neurovascular Devices Market for Stenosis, till 2035
15.7. Neurovascular Devices Market for Arteriovenous Malformations (AVMs), till 2035
15.8. Data Triangulation and Validation
16. NEUROVASCULAR DEVICES MARKET, BY END-USERS
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Neurovascular Devices Market: Distribution by End-users, 2019, current year and 2035
16.4. Neurovascular Devices Market for Hospitals and Specialty Clinics, till 2035
16.5. Neurovascular Devices Market for Ambulatory Care Centers, till 2035
16.6. Neurovascular Devices Market for Other End-users, till 2035
16.7. Data Triangulation and Validation
17. NEUROVASCULAR DEVICES MARKET, BY KEY GEOGRAPHICAL REGIONS
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Neurovascular Devices Market: Distribution by Key Geographical Regions, 2019, current year and 2035
17.4. Neurovascular Devices Market in North America, till 2035
17.5. Neurovascular Devices Market in Europe, till 2035
17.6. Neurovascular Devices Market in Asia-Pacific, till 2035
17.7. Neurovascular Devices Market in Middle East and North Africa, till 2035
17.8. Neurovascular Devices Market in Latin America, till 2035
17.9. Data Triangulation and Validation
18. NEUROVASCULAR DEVICES MARKET: KEY LEADING PLAYERS
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Neurovascular Devices Market: Distribution by Key Leading Players
18.4. Data Triangulation and Validation
19. CONCLUSION20. APPENDIX 1: TABULATED DATA21. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONLIST OF FIGURES
Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Forecast Methodology
Figure 2.3 Research Methodology: Robust Quality Control
Figure 2.4 Research Methodology: Key Market Segmentation
Figure 3.1 Lessons Learnt from Past Recessions
Figure 4.1 Executive Summary: Market Landscape
Figure 4.2 Executive Summary: Partnerships and Collaborations
Figure 4.3 Executive Summary: Funding and Investments
Figure 4.4 Executive Summary: Demand Analysis
Figure 4.5 Executive Summary: Market Forecast and Opportunity Analysis
Figure 5.1 Preventive Measures for Neurovascular Disorders
Figure 5.2 Historical Milestones in the Neurovascular Disorders Treatment
Figure 5.3 Techniques for the treatment of Neurovascular Disorders
Figure 5.4 Types of Neurovascular Devices
Figure 5.5 Challenges Associated with Neurovascular Devices
Figure 6.1 Neurovascular Devices: Distribution by Status of Development
Figure 6.2 Neurovascular Devices: Distribution by Type of Device
Figure 6.3 Neurovascular Devices: Distribution by Therapeutic Application
Figure 6.4 Neurovascular Devices: Distribution by Type of Device and Therapeutic Application
Figure 6.5 Neurovascular Devices: Distribution by Material of Fabrication
Figure 6.6 Neurovascular Devices: Distribution by Coating Material of Device
Figure 6.7 Neurovascular Device Developers: Distribution by Year of Establishment
Figure 6.8 Neurovascular Device Developers: Distribution by Company Size
Figure 6.9 Neurovascular Device Developers: Distribution by Location of Headquarters (Region)
Figure 6.10 Neurovascular Device Developers: Distribution by Location of Headquarters (Country)
Figure 6.11 Neurovascular Device Developers: Distribution by Company Size and Location of Headquarters (Region)
Figure 6.12 Most Active Developers: Distribution by Number of Neurovascular Devices Developed
Figure 7.1 Johnson & Johnson: Annual Revenues, FY 2020 Onwards (USD Million)
Figure 7.2 Medtronic: Annual Revenues, FY 2020 Onwards (USD Billion)
Figure 7.3 MicroVention: Annual Revenues, FY 2020 Onwards (Yen Billion)
Figure 7.4 Penumbra: Annual Revenues, FY 2019 Onwards (USD Million)
Figure 7.5 Stryker: Annual Revenues, FY 2019 Onwards (USD Billion)
Figure 8.1 Product Competitiveness Analysis: Neurovascular Devices Developed by Players Based in North America
Figure 8.2 Product Competitiveness Analysis: Neurovascular Devices Developed by Players Based in Europe
Figure 8.3 Product Competitiveness Analysis: Neurovascular Devices Developed by Players Based in Asia-Pacific and Rest of The World
Figure 9.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2019
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Since 2019
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 9.5 Partnerships and Collaborations: Distribution by Year and Type of Partner, Since 2019
Figure 9.6 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 9.7 Partnerships and Collaborations: Distribution by Type of Device
Figure 9.8 Partnerships and Collaborations: Distribution by Therapeutic Application
Figure 9.9 Most Active Players: Distribution by Number of Partnerships
Figure 9.10 Partnerships and Collaborations: Local and International Agreements
Figure 9.11 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Figure 10.1 Funding and Investments: Cumulative Year-wise Trend, Since 2019
Figure 10.2 Funding and Investments: Distribution by Type of Funding
Figure 10.3 Funding and Investments: Distribution by Year and Type of Funding, Since 2019
Figure 10.4 Funding and Investments: Distribution by Amount Invested, Since 2019 (USD Million)
Figure 10.5 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 10.6 Funding and Investments: Distribution by Geography (Region)
Figure 10.7 Most Active Players: Distribution by Number of Funding Instances
Figure 10.8 Most Active Players: Distribution by Amount Raised (USD Million)
Figure 10.9 Leading Investors: Distribution by Number of Funding Instances
Figure 10.10 Funding and Investment Summary, Since 2019 (USD Million)
Figure 11.1 Global Demand for Neurovascular Devices, Till 2035(Million Units)
Figure 11.2 Global Demand for Neurovascular Devices: Distribution by Type of Device, till 2035 (Million Units)
Figure 11.3 Global Demand for Neurovascular Devices: Distribution by Therapeutic Application, till 2035 (Million Units)
Figure 11.4 Global Demand for Neurovascular Devices: Distribution by Key Geographical Regions, till 2035 (Million Units)
Figure 12.1 Neurovascular Devices; Market Drivers
Figure 12.2 Neurovascular Devices; Market Restraints
Figure 12.3 Neurovascular Devices; Market Opportunities
Figure 13.1 Global Neurovascular Devices Market, till 2035 (USD Billion)
Figure 13.2 Global Neurovascular Devices Market, till 2035: Conservative Scenario (USD Billion)
Figure 13.3 Global Neurovascular Devices Market, till 2035: Optimistic Scenario (USD Billion)
Figure 14.1 Neurovascular Devices Market: Distribution by Type of Device, 2019, current year and 2035
Figure 14.2 Neurovascular Devices Market for Neurothrombectomy Devices, till 2035 (USD Million)
Figure 14.3 Neurovascular Devices Market for Embolization Devices, till 2035 (USD Million)
Figure 14.4 Neurovascular Devices Market for Angioplasty Devices, till 2035(USD Million)
Figure 15.1 Neurovascular Devices Market: Distribution by Therapeutic Application, 2019, current year and 2035
Figure 15.2 Neurovascular Devices Market for Ischemic Stroke, till 2035 (USD Million)
Figure 15.3 Neurovascular Devices Market for Aneurysm, till 2035 (USD Million)
Figure 15.4 Neurovascular Devices Market for Stenosis, till 2035 (USD Million)
Figure 15.5 Neurovascular Devices Market for Arteriovenous Malformations (AVMs), till 2035 (USD Million)
Figure 16.1 Neurovascular Devices Market: Distribution by End-users, 2019, current year and 2035
Figure 16.2 Neurovascular Devices Market for Hospitals and Specialty Clinics, till 2035 (USD Million)
Figure 16.3 Neurovascular Devices Market for Ambulatory Care Centers, till 2035 (USD Million)
Figure 16.4 Neurovascular Devices Market for Other End-users, till 2035 (USD Million)
Figure 17.1 Neurovascular Devices Market: Distribution by Key Geographical Regions, 2019, current year and 2035
Figure 17.2 Neurovascular Devices Market in North America, till 2035 (USD Million)
Figure 17.3 Neurovascular Devices Market in Europe, till 2035 (USD Million)
Figure 17.4 Neurovascular Devices Market in Asia-Pacific, till 2035 (USD Million)
Figure 17.5 Neurovascular Devices Market in Middle East and North Africa, till 2035 (USD Million)
Figure 17.6 Neurovascular Devices Market in Latin America, till 2035 (USD Million)
Figure 18.1 Neurovascular Devices Market: Distribution by Key Leading Players
Figure 19.1 Conclusion: Market Landscape
Figure 19.2 Conclusion: Partnerships and Collaborations
Figure 19.3 Conclusion: Funding and Investments
Figure 19.4 Conclusion: Demand Analysis
Figure 19.5 Conclusion: Market Forecast and Opportunity Analysis
LIST OF TABLES
Table 6.1 Neurovascular Devices Market: Information on Developer, Status of Development, Region of Approval, Type of Device, Shelf Life and Method of Sterilization
Table 6.2 Neurovascular Devices: Information on Therapeutic Application, Material of Fabrication, Coating Material of Device, Working Length, Full Length and Outer Diameter
Table 6.3 Neurovascular Devices: List of Developers
Table 7.1 List of Companies: Detailed Profiles
Table 7.2 Johnson & Johnson: Company Overview
Table 7.3 Johnson & Johnson: Neurovascular Device Portfolio
Table 7.4 Johnson & Johnson: Recent Developments and Future Outlook
Table 7.5 Medtronic: Company Overview
Table 7.6 Medtronic: Neurovascular Device Portfolio
Table 7.7 Medtronic: Recent Developments and Future Outlook
Table 7.8 MicroVention: Company Overview
Table 7.9 MicroVention: Neurovascular Device Portfolio
Table 7.10 Penumbra: Company Overview
Table 7.11 Penumbra: Neurovascular Device Portfolio
Table 7.12 Stryker: Company Overview
Table 7.13 Stryker: Neurovascular Devices Portfolio
Table 7.14 Stryker: Recent Developments and Future Outlook
Table 7.15 List of Companies: Short Profiles
Table 7.16 Acandis: Company Overview
Table 7.17 Acandis: Neurovascular Device Portfolio
Table 7.18 Achieva Medical: Company Overview
Table 7.19 Achieva Medical: Neurovascular Device Portfolio
Table 7.20 Balt: Company Overview
Table 7.21 Balt: Neurovascular Device Portfolio
Table 7.22 HeMo Bioengineering: Company Overview
Table 7.23 HeMo Bioengineering: Neurovascular Device Portfolio
Table 7.24 Phenox: Company Overview
Table 7.25 Phenox: Neurovascular Device Portfolio
Table 7.26 Shanghai HeartCare Medical Technology: Company Overview
Table 7.27 Shanghai Heartcare Medical Technology: Neurovascular Device Portfolio
Table 7.28 Zylox-Tonbridge: Company Overview
Table 7.29 Zylox-Tonbridge: Neurovascular Device Portfolio
Table 9.1 Neurovascular Devices Market: List of Partnerships and Collaborations, Since 2019
Table 9.2 Partnerships and Collaborations: Information on Location of Headquarters (Country and Region) and Type of Agreement (Country and Region)
Table 10.1 Neurovascular Devices: List of Funding and Investments, Since 2019
Table 20.1 Neurovascular Devices: Distribution by Status of Development
Table 20.2 Neurovascular Devices: Distribution by Type of Device
Table 20.3 Neurovascular Devices: Distribution by Therapeutic Application
Table 20.4 Neurovascular Devices: Distribution by Type of Device and Therapeutic Application
Table 20.5 Neurovascular Devices: Distribution by Material of Fabrication
Table 20.6 Neurovascular Devices: Distribution by Coating Material of Device
Table 20.7 Neurovascular Device Developers: Distribution by Year of Establishment
Table 20.8 Neurovascular Device Developers: Distribution by Company Size
Table 20.9 Neurovascular Device Developers: Distribution by Location of Headquarters (Region)
Table 20.10 Neurovascular Device Developers: Distribution by Location of Headquarters (Country)
Table 20.11 Neurovascular Device Developers: Distribution by Company Size and Location of Headquarters (Region)
Table 20.12 Most Active Developers: Distribution by Number of Neurovascular Devices Developed
Table 20.13 Johnson & Johnson: Annual Revenues, FY 2020 Onwards (USD Million)
Table 20.14 Medtronic: Annual Revenues, FY 2020 Onwards (USD Billion)
Table 20.15 MicroVention: Annual Revenues, FY 2020 Onwards (Yen Billion)
Table 20.16 Penumbra: Annual Revenues, FY 2019 Onwards (USD Million)
Table 20.17 Stryker: Annual Revenues, FY 2019 Onwards (USD Billion)
Table 20.18 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2019
Table 20.19 Partnerships and Collaborations: Distribution by Type of Partnership
Table 20.20 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Since 2019
Table 20.21 Partnerships and Collaborations: Distribution by Type of Partner
Table 20.22 Partnerships and Collaborations: Distribution by Year and Type of Partner, Since 2019
Table 20.23 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 20.24 Partnerships and Collaborations: Distribution by Type of Device
Table 20.25 Partnerships and Collaborations: Distribution by Therapeutic Application
Table 20.26 Most Active Players: Distribution by Number of Partnerships
Table 20.27 Partnerships and Collaborations: Local and International Agreements
Table 20.28 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Table 20.29 Funding and Investments: Cumulative Year-wise Trend, Since 2019
Table 20.30 Funding and Investments: Distribution by Type of Funding
Table 20.31 Funding and Investments: Distribution by Year and Type of Funding, Since 2019
Table 20.32 Funding and Investments: Distribution by Amount Invested, Since 2019 (USD Million)
Table 20.33 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
Table 20.34 Funding and Investments: Distribution by Geography (Region)
Table 20.35 Most Active Players: Distribution by Number of Funding Instances
Table 20.36 Most Active Players: Distribution by Amount Raised (USD Million)
Table 20.37 Leading Investors: Distribution by Number of Funding Instances
Table 20.38 Funding and Investment Summary, Since 2019 (USD Million)
Table 20.39 Global Demand for Neurovascular Devices, till 2035 (Million Units)
Table 20.40 Global Demand for Neurovascular Devices: Distribution by Type of Device, till 2035 (Million Units)
Table 20.41 Global Demand for Neurovascular Devices: Distribution by Therapeutic Application, till 2035 (Million Units)
Table 20.42 Global Demand for Neurovascular Devices: Distribution by Key Geographical regions, till 2035 (Million Units)
Table 20.43 Global Neurovascular Devices Market, till 2035 (USD Million)
Table 20.44 Global Neurovascular Devices Market, till 2035: Conservative Scenario (USD Million)
Table 20.45 Global Neurovascular Devices Market, till 2035: Optimistic Scenario (USD Million)
Table 20.46 Neurovascular Devices Market: Distribution by Type of Device, 2019, current year and 2035
Table 20.47 Neurovascular Devices Market for Neurothrombectomy Devices, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.48 Neurovascular Devices Market for Embolization Devices, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.49 Neurovascular Devices Market for Angioplasty Devices, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.50 Neurovascular Devices Market: Distribution by Therapeutic Application, 2019, current year and 2035
Table 20.51 Neurovascular Devices Market for Ischemic Stroke, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.52 Neurovascular Devices Market for Aneurysm, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.53 Neurovascular Devices Market for Stenosis, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.54 Neurovascular Devices Market for Arteriovenous Malformations (AVMs), till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.55 Neurovascular Devices Market: Distribution by End-users, 2019, current year and 2035
Table 20.56 Neurovascular Devices Market for Hospitals and Specialty Clinics, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.57 Neurovascular Devices Market for Ambulatory Care Centers, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.58 Neurovascular Devices Market for Other End-users, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.59 Neurovascular Devices Market: Distribution by Key Geographical Regions, 2019, current year and 2035
Table 20.60 Neurovascular Devices Market in North America, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.61 Neurovascular Devices Market in Europe, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.62 Neurovascular Devices Market in Asia-Pacific, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.63 Neurovascular Devices Market in Middle East and North Africa, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.64 Neurovascular Devices Market in Latin America, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.65 Neurovascular Devices Market: Distribution by Key Leading Players